Prestige Consumer Healthcare Inc. (PBH)
NYSE: PBH · Real-Time Price · USD
85.06
+0.44 (0.52%)
Jun 6, 2025, 4:00 PM - Market closed
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
| North American OTC Healthcare | 960.01M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North American OTC Healthcare Growth | 0.18% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International OTC Healthcare | 177.75M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International OTC Healthcare Growth | 6.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Analgesics | 117.70M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Analgesics Growth | 0.21% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cough & Cold | 106.21M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cough & Cold Growth | -10.76% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Women's Health | 236.83M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Women's Health Growth | -1.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Gastrointestinal | 255.94M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Gastrointestinal Growth | 10.51% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eye & Ear Care | 183.32M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eye & Ear Care Growth | 2.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Dermatologicals | 128.95M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Dermatologicals Growth | -0.12% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oral Care | 95.03M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oral Care Growth | -1.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other OTC | 13.78M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other OTC Growth | 14.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Gross Income by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
| North American OTC Healthcare Gross Margin | 531.14M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North American OTC Healthcare Gross Margin Growth | 12.83% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International OTC Healthcare Gross Margin | 103.32M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International OTC Healthcare Gross Margin Growth | 7.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
| North American OTC Healthcare Contribution Margin | 401.71M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North American OTC Healthcare Contribution Margin Growth | 18.05% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International OTC Healthcare Contribution Margin | 77.03M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International OTC Healthcare Contribution Margin Growth | 8.26% |
Log In |
Log In |
Log In |
Log In | Upgrade
|